Myriad Genetics, Inc.
NASDAQMyriad Genetics arrives at its August 4 earnings release as a stock already in freefall — down 47% in a single session on July 31 and nearly 50% on the week, following a quarterly print on July 30 that triggered a 43% one-day collapse. The wreckage from that print defines the entire setup heading into Tuesday. The stock closed at $2.86, less than half the $5.32 level at which it…
Snapshot as of 6 Aug 2026
Myriad Genetics arrives at its August 4 earnings release as a stock already in freefall — down 47% in a single session on July 31 and nearly 50% on the week, following a quarterly print on July 30 that triggered a 43%…
Myriad Genetics arrives at its July 30 earnings release down 10% on the week and carrying the memory of a 17% one-day collapse after its last quarterly print in May. The stock closed at $5.32 on Tuesday, extending a…
Myriad Genetics heads into the post-earnings stretch with the stock trading close to multi-year lows, still loss-making at the operating level, and the Street in a cautious but not dismissive mood — a setup defined…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MYGN — free to start on ORTEX.
Sign up for free →Open MYGN on ORTEX